MNOV Stock Overview
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MediciNova, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.33 |
| 52 Week High | US$2.66 |
| 52 Week Low | US$1.26 |
| Beta | 0.69 |
| 1 Month Change | -3.62% |
| 3 Month Change | -11.92% |
| 1 Year Change | -37.85% |
| 3 Year Change | -72.46% |
| 5 Year Change | -87.97% |
| Change since IPO | -87.85% |
Recent News & Updates
Recent updates
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Apr 19
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Nov 27We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Jul 11Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation
Mar 18We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
Oct 12MediciNova to get US patent for MN-166 to treat brain cancer
Sep 15MediciNova's MN-166 to be part of study to treat Long COVID
Aug 16MediciNova begins study of parenteral formulation of MN-166
Jul 22MediciNova announces extension of BARDA contract for Ibudilast development
Jun 30We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Mar 19MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business
Nov 23MediciNova: The Pain Of A Positive Outlook
Aug 31MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study
Jun 21Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
May 15The MediciNova Riddle: Worth Unravelling
Apr 26MediciNova inks $20M securities purchase agreement with 3D Investment Partners
Jan 12MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis
Dec 29MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Dec 29
MediciNova selected for the Nasdaq Biotechnology Index
Dec 15MediciNova's MN-166 can reduce retinal thinning in progressive multiple sclerosis
Nov 25Shareholder Returns
| MNOV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.0% | 1.5% | 1.2% |
| 1Y | -37.9% | 1.1% | 24.7% |
Return vs Industry: MNOV underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: MNOV underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| MNOV volatility | |
|---|---|
| MNOV Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MNOV has not had significant price volatility in the past 3 months.
Volatility Over Time: MNOV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 13 | Yuichi Iwaki | www.medicinova.com |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company’s product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.
MediciNova, Inc. Fundamentals Summary
| MNOV fundamental statistics | |
|---|---|
| Market cap | US$65.23m |
| Earnings (TTM) | -US$8.57m |
| Revenue (TTM) | US$1.00m |
65.2x
P/S Ratio-7.6x
P/E RatioIs MNOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNOV income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.00m |
| Other Expenses | US$9.57m |
| Earnings | -US$8.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 100.00% |
| Net Profit Margin | -857.15% |
| Debt/Equity Ratio | 0% |
How did MNOV perform over the long term?
See historical performance and comparison